Samsung Bioepis has successfully opposed Janssen Biotech’s AU2019346134 patent application for methods of treating ulcerative colitis with ustekinumab (Stelara®). Samsung invalidated all of the AU134 claims on the grounds of lack of novelty and obviousness.
IP Australia has dismissed Adama Agan Ltd’s (Adama) opposition to the grant of Kumiai Chemical Industry Co., Ltd’s (Kumiai) Australian patent application directed to an industrial process for producing the herbicide pyroxasulfone, with Kumiai’s patent application proceeding to grant in early January 2026.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 30 January 2026 are set out below…
Justice Beach of the Federal Court of Australia has granted an appeal by CSIRO overturning the APO decision that CSIRO’s patent application number AU 2017292900 (the Application) was invalid due to lack of support.
In Southern Cross Industrial Group Pty Ltd v Mickala Mining Maintenance Pty Ltd (Liability Trial) [2025] FCA 1363, Justice Downes of the Federal Court found an innovation patent for LED lighting towers invalid for lack of novelty and innovative step.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 23 January 2026 are set out below…
Justice Jackman of the Federal Court has handed down judgment in proceedings between Abbey Laboratories Pty Ltd. (Abbey) and Virbac Australia Pty Ltd (Virbac), in a dispute concerning Virbac’s patent for a veterinary topical pour-on formulation for cattle containing macrocyclic lactone and levamisole.
The Australian Patent Office (APO) upheld an opposition by Nuseed Pty Ltd and Norddeutsche Pflanzenzucht Hans Georg Lembke KG against Limagrain Europe’s Australian patent application number 2016307234 (the Application) relating to Brassica…
The Australian Patent Office (APO) upheld an opposition by Urrbrae Foods Pty Ltd against CSIRO’s patent application number AU2017292900 (the Application) directed to high amylose wheat. While grounds of manner of manufacture and entitlement…
Mediation is set to become a more prominent feature of New Zealand’s legal landscape, including in intellectual property disputes. Mediation will be strongly encouraged in cases placed on the new, fast-track Commercial List in the High Court of New Zealand.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 16 January 2026 are set out below…
Seqirus, Inc. opposed Translate Bio, Inc.’s patent application (AU2020202755) concerning the in vivo delivery of mRNA for augmenting proteins and enzymes in genetic diseases. The invention’s contribution lay in specific liposome-forming lipid…
This decision concerns the apportionment of costs arising from the substantive decision in Miele & Cie KG v Bruckbauer [2025] FCA 537 (27 May 2025) (Substantive Decision). Justice Rofe considered the appropriate apportionment of costs…
Pearce IP and Chantal Savage, have been ranked in Australia for Intellectual Property in the Legal 500 Asia Pacific 2026 Rankings. Legal 500 rankings take in a broad scope of client and law firm information, combining qualitative and quantitative data to create a strategic compass for clients who are searching for the best legal advisers for their type of work.
Justice Jackman has confirmed that, in the context of a preliminary discovery application, where a prospective applicant vacates a hearing date and the prospective respondent has incurred costs in preparing for the vacated hearing…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the prior three weeks ending 9 January 2026 are set out below…
Newron Pharmaceuticals and Zambon have succeeded in their preliminary discovery application against Arrotex Pharmaceuticals in the Federal Court of Australia. Newron and Zambon sought production of documents from Arrotex, for the purpose of…
Justice Rofe has handed down an interlocutory judgment dismissing Zoetis Australia Pty Ltd’s (Zoetis) application for summary dismissal of Scidera, Inc.’s (Scidera) patent infringement claims. The decision addresses a novel question of Australian patent law…
In a lengthy 1300+ paragraph judgment, Justice Downes has handed victory to Orica, finding that Orica achieved “almost complete success” in its infringement case regarding three of the four patents in suit…
Pearce IP’s CEO and Founder, Naomi Pearce, has been recognised in the IAM Strategy 300 Global Leaders 2026 – the annual showcase of the world’s leading IP strategists. This latest honour follows her previous inclusions in 2020, 2021 and 2022.
Pearce IP’s Head of Litigation (NZ), Paul Johns, explores the usefulness of Swiss-type claims in New Zealand patents, including comparisons of key points of law and practice in other countries. He discusses the particular requirements for Swiss claims under New Zealand practice, contrasts the law and practice…
No Relief for EIS – Federal Court Invalidates Pressure Wave Massager Patent and Dismisses Infringement Claims Against LELO
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 19 December 2025 are set out below…
Justice Burley of the Federal Court has delivered judgment in proceedings between CPC Patent Technologies Pty Ltd (CPC) and Apple Pty Limited and Apple Inc (collectively, Apple), concerning alleged patent infringement by Apple’s biometric security…
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
